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SUMMARY. In this study, matrix type patch formulations of flurbiprofen using certain skin permeation
enhancers [isopropyl myristate (IPM), isopropyl palmitate (IPP) and Tween 80] were formulated, evaluat-
ed and compared. The cumulative amounts permeated and the permeation rates were higher for the pre-
pared formulations as compared to the controls (without enhancers). The results also revealed better skin
permeation characteristics of flurbiprofen using IPM than other enhancers. The pharmacokinetic param-
eters of the optimized formulation (F7), calculated from the blood levels of the drug, revealed a profile
with the ability to maintain adequate plasma levels for 24 h (i.e. up to the next application): AUC(0-24)
10.406 ± 1.34ng.h/ml, Tmax 1.5 ± 0.91 and Cmax 1.3049 ± 0.21 μg.ml–1. The amount of drug bioavailable for
targeting the site of action is comparable to that of market control. Based on experimental results, prepa-
ration of 10 % flurbiprofen matrix type patch formulation containing IPM is promising.
